147 related articles for article (PubMed ID: 19887957)
21. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?].
Valat JP; Deray G; Héloire F
Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550
[TBL] [Abstract][Full Text] [Related]
22. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh EV; Lally ET; Moore PA
Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular issues of COX-2 inhibitors and NSAIDs.
Wong M; Chowienczyk P; Kirkham B
Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629
[TBL] [Abstract][Full Text] [Related]
24. The anti-proliferative potency of celecoxib is not a class effect of coxibs.
Schiffmann S; Maier TJ; Wobst I; Janssen A; Corban-Wilhelm H; Angioni C; Geisslinger G; Grösch S
Biochem Pharmacol; 2008 Jul; 76(2):179-87. PubMed ID: 18547544
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular Risk of Nonsteroidal Anti-inflammatory Drugs and Classical and Selective Cyclooxygenase-2 Inhibitors: A Meta-analysis of Observational Studies.
Martín Arias LH; Martín González A; Sanz Fadrique R; Vazquez ES
J Clin Pharmacol; 2019 Jan; 59(1):55-73. PubMed ID: 30204233
[TBL] [Abstract][Full Text] [Related]
26. Predictors of the selection of coxibs over nonselective NSAIDs in an older Medicaid cohort.
Shireman TI; Rigler SK
Am J Geriatr Pharmacother; 2006 Sep; 4(3):210-8. PubMed ID: 17062321
[TBL] [Abstract][Full Text] [Related]
27. The novel anti-inflammatory agent VA694, endowed with both NO-releasing and COX2-selective inhibiting properties, exhibits NO-mediated positive effects on blood pressure, coronary flow and endothelium in an experimental model of hypertension and endothelial dysfunction.
Martelli A; Testai L; Anzini M; Cappelli A; Di Capua A; Biava M; Poce G; Consalvi S; Giordani A; Caselli G; Rovati L; Ghelardini C; Patrignani P; Sautebin L; Breschi MC; Calderone V
Pharmacol Res; 2013 Dec; 78():1-9. PubMed ID: 24083950
[TBL] [Abstract][Full Text] [Related]
28. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
29. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
Zhang J; Ding EL; Song Y
JAMA; 2006 Oct; 296(13):1619-32. PubMed ID: 16968832
[TBL] [Abstract][Full Text] [Related]
30. Non-steroidal anti-inflammatory drugs and cardiac failure: meta-analyses of observational studies and randomised controlled trials.
Scott PA; Kingsley GH; Scott DL
Eur J Heart Fail; 2008 Nov; 10(11):1102-7. PubMed ID: 18760966
[TBL] [Abstract][Full Text] [Related]
31. Cyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidases.
Li H; Hortmann M; Daiber A; Oelze M; Ostad MA; Schwarz PM; Xu H; Xia N; Kleschyov AL; Mang C; Warnholtz A; Münzel T; Förstermann U
J Pharmacol Exp Ther; 2008 Sep; 326(3):745-53. PubMed ID: 18550689
[TBL] [Abstract][Full Text] [Related]
32. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
33. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly.
Stillman MJ; Stillman MT
Geriatrics; 2007 Mar; 62(3):16-21. PubMed ID: 17346094
[TBL] [Abstract][Full Text] [Related]
34. Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts.
Tacconelli S; Bruno A; Grande R; Ballerini P; Patrignani P
Expert Opin Drug Saf; 2017 Jul; 16(7):791-807. PubMed ID: 28569569
[TBL] [Abstract][Full Text] [Related]
35. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
36. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
Fosslien E
Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
39. [NSAIDs and coxibs raise blood pressure].
Krankenpfl J; 2005; 43(7-10):199. PubMed ID: 16515271
[No Abstract] [Full Text] [Related]
40. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
